PERSPECTA

News from every angle

← Back to headlines

Wells Fargo Rates BioMarin Pharmaceutical Inc. (BMRN) Overweight Despite Study Discontinuations

Wells Fargo has given BioMarin Pharmaceutical Inc. (BMRN) an "Overweight" rating, despite the discontinuation of its Voxzogo Phase 2 study.

30 Mar, 11:10 — 30 Mar, 11:10
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual18d ago

BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations

Read full article →

Related Stories

Brazilian President Lula da Silva shares longevity advice

14m ago

Russia reportedly tests ammunition and drugs on humans

14m ago

Kangana Ranaut comments on Deepika Padukone's 8-hour work shift demand

15m ago

Single mother and top runner Eva Wutti to compete in Vienna City Marathon

15m ago